Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 TAS-102 (TFTD) + bevacizumab in elderly unresectable colorectal cancer
jRCTs071180065Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival. Started Jan 2017; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs071180065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180065.